Abstract
The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.
| Original language | English |
|---|---|
| Pages (from-to) | 2591-2593 |
| Number of pages | 3 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 51 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2007 Jul 1 |
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Fingerprint Dive into the research topics of 'In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea'. Together they form a unique fingerprint.
Cite this
Jong, H. Y., Chang, K. K., Yong, D., Lee, K., Chong, Y., Cheol, M. K., Jeong, M. K., Ro, S., & Joong, M. C. (2007). In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrobial agents and chemotherapy, 51(7), 2591-2593. https://doi.org/10.1128/AAC.01562-06